Founders With the support of Results4th Call for Projects NeuroPrion2010 Salzburg.

Slides:

Advertisements

Similar presentations

Distinctive characteristics

Advertisements

1 Chapter 50 Molecular Basis of Prion Diseases Copyright © 2012, American Society for Neurochemistry. Published by Elsevier Inc. All rights reserved.

Use of PMCA for Biochemical Diagnosis of Prion Diseases Claudio Soto, PhD Dept of Neurology, University of Texas Medical Branch and Amprion Inc.

Presence of “Mad Cow Disease” (Bovine Spongiform Encephalopathy) and Natural Scrapie in Ovine Transgenic Mice (TgOvPrP4) Christina Hill Department of Biological.

Removal of Prions by Plasma Fractionation Processes

Silvia Maria DOGLIA Nanoparticelle di aggregati proteici DIPARTIMENTO DI BIOTECNOLOGIE E BIOSCIENZE.

Mouse Prion Protein Domain PrP( ) Andreas Razen Geometric Computations in Molecular Biology 2 May 2007.

1 Transmissible Spongiform Encephalopathies. 2 Kuru Since the early 1900’s the Fore people of New Guinea have honored their dead by cooking and consuming.

CLINICAL ASPECTS OF BIOCHEMISTRY NEURODEGENERATIVE DISEASES Prion diseases Alzheimer's disease.

Topic 1. Validation of Procedures to Prevent Contamination and Cross-Contamination with TSE Agents of Human Tissue Intended for Transplantation TSEAC June.

PRION DISEASE & PENTOSAN POLYSULPHATE IN THE UK Richard Knight NCJDSU University of Edinburgh Scotland.

Biotechnology and Medicine Esmaeil Sadroddiny, PhD Medical Biotechnology.

Holly Allen CREUTZFELDT-JAKOB DISEASE.  Human equivalent of mad cow disease  Rare, degenerative, fatal disease  Approximately 1 case per million per.

BIOCHEMISTRY DR AMENA RAHIM. Structure of Elastin It is a connective tissue protein Rubber like properties Elastin & glycoprotein microfibrils are present.

Pronucleon TM Amplified Misfolded Protein Diagnostic Assay (AMP-D) Kenton L. Lohman, Ph.D. VP Assay Development Adlyfe Inc., Rockville, MD.

Transmissible Spongiform Encephalopathies (TSEs) a.k.a. Prion Diseases Transmissible  can be spread Spongiform  resembling a sponge Encephalopathies.

Prions: Proteins Gone Bad

Decontamination of Surfaces Contaminated with Prions Dr. Gerald McDonnell.

Field-Induced Magnetic Nanoparticle Drug Delivery BME 273 Group 15 Team Leader : Ashwath Jayagopal (BME, EE, MATH) Members : Sanjay Athavale (BME) and.

Labs start today, or Thursday Inquiry 1 proposal due 9/9 or 9/13 Class communication via Blackboard, webpage, and/or .

1 HPerron TSEAC Detection of PrP res in plasma H. Perron Presented by P van Driessche.

Prions and Protein Misfolding BICH 107 GENE 105. Kuru Discovered in Papua New Guinea in early 1900's "Trembling with fear" Characterized by headaches,

Diagnostics Alan S. Rudolph PhD MBA Chief Executive Officer Adlyfe Inc. Rockville, MD Innovation is in our blood Diagnostics.

Proposed algorithm for approval of human TSE tests in Europe.

Removal of Infectious Prions from Red Cell Concentrates Samuel Coker, PhD Principal Scientist and Technical Director Pall Medical Transmissible Spongiform.

Prion Digestion in the Alimentary Tract Nicholas Toney.

Today: A little more Strong Inference Why are you connected to polar bears? How do we know that anyone else knows anything?

12 August 2003 CJD Update Latest facts, figures & findings Jonathan P Clewley TSE Unit, Virus Reference Division, Centre for Infections 20 May 2005.

Laboratory of Cellular Hematology

1 Laboratory of Bacterial, Parasitic and Unconventional Agents (LBPUA) Research Programs Report to BPAC 13 July 2006 Site Visit by Ad Hoc Review Committee.

John Gray, Sandor Dudas and Stefanie Czub

19 September 2006 Gaithersburg, MD David Peretz M.Sc., D.Sc. Senior Scientist CHIRON Submission To FDA TSE Advisory Committee Meeting.

C B E R E R Vostal 10/2005 Labeling Claims for TSE Reduction Studies with Blood Processing Filters Jaro Vostal, M.D., Ph.D. Division of Hematology, OBRR.

TSE Agent Clearance Issues TSE Advisory Committee February 20, 2003 Dorothy Scott, M.D. DH/OBRR/CBER/FDA.

TSE Clearance in Plasma Derivatives TSE Advisory Committee February 8, 2005 Dorothy Scott, M.D. DH/OBRR/CBER/FDA.

Founders With the support of. 2 Letters of intent  Individual quotation, then selection by the SAB Validation by the Bureau  Full Application  Individual.

Treatment of Protein Misfolding Diseases with Novel Biologics

The Seprion Separation System Development of a feasible blood screening protocol for abnormal prion protein Stuart Wilson Microsens Biotechnologies.

The History of Chronic Wasting Disease Dr. Trent Bollinger, CCWHC One World, One Health Symposium Sept. 29, 2004.

Removal of Infectious Prions from Red Cell Concentrates Blood Safety Advisory Committee March 17, 2005 Joseph Cervia, M.D., FACP,FAAP Professor of Clinical.

Labs start next week (first reflection due)

TSE Task Force Prion reduction evaluation in the manufacturing of plasma protein therapies Dr. Henry Baron, Chair, PPTA TSE Task Force.

Prions “Scrapie” “mad cow disease” Nobel Prize 1997

Microbes and Diseases Chapter 02. CREUTZFELDT-JAKOB DISEASE Prion.

FDA Risk Management Strategy for Potential Exposure to vCJD from Plasma Derivatives TSE Advisory Committee December 15, 2006 Dorothy Scott, M.D. OBRR/CBER.

Dr. Stuart Reichler Bio 311D. DateSubjectTextbook Chapters Jan 14Introduction, Philosophy of Science 16Strong Inferencearticle on webpage 18, 23Meiosis12,

TOPIC II Potential Screening Assays to Detect Blood and Plasma Donors Infected with TSE Agents: Possible Criteria for Validation Pedro Piccardo, MD LBPUA,

Proteolytic Inactivation of prions; a biological solution to TSE decontamination. Dickinson J*, Murdoch H*, Sutton JM*, Crabb, W. D.#, Bott, R#, Penet,

Creutzfeldt-Jakob Disease Atif Chohan & Alex Brown.

Aya Murakami. Background Transmissible Spongiform Encephalopathies and Prion Other for TSEs CWD Distribution in the US Symptoms and Diagnosis Biomarkers.

CyclinD1/CyclinD3 Ratio by Real-Time PCR Improves Specificity for the Diagnosis of Mantle Cell Lymphoma Carol D. Jones, Katherine H. Darnell, Roger A.

VARIANT CREUTZFELDT-JACOB DISEASE (vCJD) AND GASTROINTESTINAL ENDOSCOPY.

+ High CJD infectivity remains after the prion protein is destroyed By Sylvester Gates.

Martine Bruley Rosset UMR S 938 INSERM Hôpital St Antoine Paris France

(Bovine spongiform encephalopathy)

Diseases caused by bacteria and viruses

Disease Transmission and Species Barrier

Disease-Associated Prion Protein in Vessel Walls

In Vitro Generation of Infectious Scrapie Prions

Recombinant Vaccines A recombinant vaccine is a vaccine produced through recombinant DNA technology. This involves inserting the DNA encoding an antigen.

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Real-Time Polymerase Chain Reaction Detection of Herpes Simplex Virus in Cerebrospinal Fluid and Cost Savings from Earlier Hospital Discharge Kenneth.

Mammalian Prion Biology

Putative targets of miRNAs directly induced by p53 with down-regulated mRNA- and de novo protein synthesis or reduced de novo protein synthesis only. Putative.

Volume 134, Issue 5, Pages (September 2008)

A Template for New Drugs against Alzheimer’s Disease

Real-time quaking-induced conversion reactions seeded with cerebrospinal fluid from a patient with sporadic Creutzfeldt-Jakob disease (sCJD) (red) and.

Western blot analysis of skin tissue from CJD and non-CJD patients

Real-Time Polymerase Chain Reaction Detection of Herpes Simplex Virus in Cerebrospinal Fluid and Cost Savings from Earlier Hospital Discharge Kenneth.

Presentation transcript:

Founders With the support of Results4th Call for Projects NeuroPrion2010 Salzburg

2 Letters of intent  Independent evaluation and selection by the SAC Validation by the Bureau  Full Application  Independent evaluation and selection by the SAC Proposal to the Bureau  Selection and validation by the Executive Committee Selection process

3 Selected Projects UltraMab High affinity anti-PrP monoclonal antibodies from PrP-negative hybridomas Investigators: Adriano Aguzzi, Paolo Dametto, Simone Hornemann (University Hospital of Zürich, Switzerland)

4 Selected Projects CJD-diagnostic Detection of PrP TSE surface-bound aggregates by Fluorescence Intensity Distribution Analysis Investigator: Dr. Eva Birkmann (Heinrich-Heine-University Düsseldorf, Germany )

5 Selected Projects SMAD-Prion Statistical methodology for assessing prion decontamination procedures Investigator: Pierre-Yves Boëlle (Paris VI University, France)

6 Selected Projects RAP-Experimental Treatment Experimental treatment of TSE-infected cell cultures and sCJD-infected HuTg mice with RAP, a protein folding chaperone Investigators: Dr Larisa Cervenakova, Elena Semenova, Oksana Yakovleva, Carroll McKenzie (American Red Cross, Rockville, USA)

7 Selected Projects CSF Real-time QuiC Development and evaluation of a diagnostic test for sporadic and variant CJD based on detection of PrP TSE in the cerebrospinal fluid using real- time QuiC analysis Investigators: Dr Alison Green, Dr Lynne McGuire, Dr Mark Head, Pr Robert Will, Pr Richard Knight (NCJDSU, Edinburgh, UK)

8 Selected Projects Sheep BSE In vitro model of risk to humans if the molecular signature of BSE in sheep during serial PMCA becomes indistinguishable from scrapie’ but retains its human pathogenicity Investigators: Dr Mark Head, (NCJDSU, Edinburgh,UK) Dr Lorenzo González, (VLA Lasswade, UK) Dr Michael Jones, (SNBTS, UK)

9 Selected Projects Surf-PMCA Use of contaminated metal wires as PMCA templates for the evaluation of prion decontamination procedures. Investigators: Pr Sylvain Lehmann, Dr Carole Crozet (CNRS Montpellier, France) Dr Joliette Coste, Dr Daisy Bougard (EFS PM, France), Dr Hubert Laude, Vincent Béringue (INRA, Jouy-en- Josas, France)

10 Selected Projects TransGlutam Transglutaminase – a facilitating enzyme common to the protein misfolding family? Investigators: Dr Cindy S. Orser, (iPDx Biosciences, Boulder, USA) Pr Herbert Budka (Medical University, Vienna, Austria)

11 Selected Projects PrPdetection Detection of prions in biological fluids and tissues using Thienyl Pyrimidine compounds (enhanced PK resistance of PrP TSE ) Investigator: Dr Véronique PERRIER ( INSERM, Montpellier University, France)

12 Selected Projects Nanoparticle prion capture Magnetic nanoparticle capture/removal of PrP TSE from blood followed by PMCA detection Investigators: Surachai Supattapone, Michael Miller (Dartmouth Medical School, USA)